Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Running, not enrolling · Phase 1

Conditions studied: Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer

In brief

This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H\&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.

Key facts

Study ID

NCT03170960

Run by

Exelixis

People needed

914

Starts

2017-09-05

Expected to finish

2027-09-30

Last updated by the study team

2025-08-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent:
• Dose-Escalation Stage:
• Subjects with UC (including renal pelvis, ureter, bladder, urethra) after prior platinum-based therapy, or
• Subjects with RCC (clear cell, non-clear cell histology) with or without prior systemic anticancer therapy
• Expansion Stage:
• Inoperable locally advanced or metastatic solid tumor (UC, RCC, CRPC, NSCLC, TNBC, OC, EC, HCC, GC/GEJC/LEC, CRC, H\&N cancer, and DTC as outlined above)
• Measurable disease per RECIST 1.1 as determined by the investigator.
• Tumor tissue material available (archival or recent tumor biopsy)
• Recovery to baseline or ≤ Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
• Age eighteen years or older on the day of consent.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Adequate organ and marrow function.
• Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception.
• Female subjects of childbearing potential must not be pregnant at screening.

You may not qualify if…

• Prior treatment with cabozantinib or immune checkpoint inhibitors including anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy except in Expansion Cohorts 5, 7, 9, 11, 17, 19 and 20. Other restrictions regarding prior therapy may apply.
• Known brain metastases or cranial epidural disease unless adequately treated and stable for at least 4 weeks before first dose of study treatment.
• Concomitant anticoagulation with oral anticoagulants.
• Subject is receiving systemic steroid therapy (>10 mg daily prednisone equivalent) or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment.
• Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.
• The subject has uncontrolled, significant intercurrent or recent illness, including, but not limited to, an active or history of autoimmune disease or immune deficiency; idiopathic pulmonary fibrosis, organizing pneumonia, pneumonitis; active infection requiring systemic treatment, infection with human immunodeficiency virus (HIV), AIDS-related illness, acute or chronic hepatitis B or C infection, positive test for tuberculosis, moderate to severe hepatic impairment (Child-Pugh B or C).
• Pregnant or lactating females.
• Previously identified allergy or hypersensitivity to components of the study treatment formulations.
• Diagnosis of another malignancy within 2 years before first dose of study treatment.

Where it is running

• Exelixis Clinical Site #18 — Phoenix, Arizona, United States
• Exelixis Clinical Site #1 — Duarte, California, United States
• Exelixis Clinical Site #20 — La Jolla, California, United States
• Exelixis Clinical Site #46 — Los Angeles, California, United States
• Exelixis Clinical Site #51 — Newport Beach, California, United States
• Exelixis Clinical Site #62 — Santa Monica, California, United States
• Exelixis Clinical Site #21 — Stanford, California, United States
• Exelixis Clinical Site #34 — Denver, Colorado, United States
• Exelixis Clinical Site #50 — Denver, Colorado, United States
• Exelixis Clinical Site #42 — New Haven, Connecticut, United States
• Exelixis Clinical Site #48 — Washington D.C., District of Columbia, United States
• Exelixis Clinical Site #16 — Jacksonville, Florida, United States
• Exelixis Clinical Site #76 — Tampa, Florida, United States
• Exelixis Clinical Site #60 — Atlanta, Georgia, United States
• Exelixis Clinical Site #79 — Atlanta, Georgia, United States
• Exelixis Clinical Site #32 — Harvey, Illinois, United States
• Exelixis Clinical Site #23 — Fairway, Kansas, United States
• Exelixis Clinical Site #57 — Lexington, Kentucky, United States
• Exelixis Clinical Site #24 — New Orleans, Louisiana, United States
• Exelixis Clinical Site #10 — Boston, Massachusetts, United States
• Exelixis Clinical Site #3 — Detroit, Michigan, United States
• Exelixis Clinical Site #17 — Rochester, Minnesota, United States
• Exelixis Clinical Site #65 — Bolivar, Missouri, United States
• Exelixis Clinical Site #43 — Kansas City, Missouri, United States
• Exelixis Clinical Site #53 — Gilbert, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.